Freedom Leaf Announces Further Expansion in Overseas Markets
Starting With New Products In Europe; This Puts FRLF at Forefront
of Therapeutic Cannabinoid Industry, Collaborating With Two
European Firms for Global Sales of Freedom Leaf Branded CBG
Products
LAS VEGAS, NV--(NewMediaWire - Aug 10, 2017) - Freedom Leaf,
Inc, (OTCQB: FRLF) The Marijuana Legalization Company ™, is
pleased to announce that it is collaborating with two privately
owned European companies for product development and global
marketing to provide a variety of Freedom Leaf branded products
with Rare
Cannabinoids, CBG, (Cannabigerol) in
addition to its
popular CBD, Cannabidiol.
Freedom Leaf, Inc., CEO Clifford J. Perry announced, "These new
products, along with our hempOLOGY brand
products, will put Freedom Leaf at the forefront of the therapeutic
cannabinoid industry."
Perry has hailed Freedom Leaf Iberia licensee, Federico Pando,
for his work in bringing these new products to the
public. Freedom Leaf is staking its claim to foreign markets
starting with Europe with plans to be in Central and South America
as well as other countries around the world. The market for
Hemp is expanding in many countries even faster than the United
States. Serious revenue is available from exploring these
different markets around the world.
Mr. Pando also was instrumental in Freedom Leaf's recently
signed Letter of Intent to acquire the Spanish organic hemp
grower, Green Market Europe, and the acquisition of the
Spanish websites, LaMarihuana.com, the oldest and most popular
Spanish language cannabis website,
and Marihuana-Medicinal.com, the biggest Spanish language
medical cannabis site.
Mr. Pando explained that the CBG
(Cannabigerol) crystal and other cannabinoids can be
added to a variety of products, including the transdermal patches
that Freedom Leaf is developing in collaboration with a privately
owned European firm with more than 20 years' experience in
transdermal technology.
The Cannabigerol crystal has a 97%
purity and comes with Food
Grade HACCP, Hazard analysis and
critical control points and GMP, Good Manufacturing
Practices certification. The plant comes from an EU Certified
Industrial Hemp strain and CBG is not
psychoactive it can be sold over the counter in many countries.
The Hemp strain used has the rarest chemotaxonomy (Level 4)
which only produces CBG.
Although no medical claims are being made for any of the
products, in various studies there are indications that
Cannabigerol may relieve pain, reduce seizures and convulsions,
slow bacterial growth in certain species, reduce inflammation
systemically, induce sleep, inhibit cancer cell growth, stimulate
the growth of new brain cells and promotes bone growth. Some of the
other conditions under study include glaucoma, inflammatory bowel
diseases, anti-inflammatory disorders, epilepsy and chronic
pain.
CBG samples have already been shipped and
delivered to product development facilities in Colorado and
California.
Freedom Leaf, Inc. is currently collaborating with Spanish
scientists isolating other rare cannabinoids.
Some of the ongoing research includes strains
with THCV, Tetrahydrocannabivarin which suppresses
appetite and CBC, Cannabichromene which
has been shown to aid with depression.
Pando stated, "Our transdermal patches will have a very
competitive price and be sold over the counter and online
worldwide. We expect to have an aggressive online marketing
campaign to get the attention of mainstream consumers who have not
been cannabis users."
The transdermal patches will be available in 2018, but other
products containing CBG and some Freedom
Leaf branded rare cannabinoids may be
available in the fourth quarter of this year.
Freedom Leaf´s hempOLOGY brand is already marketing
its unique combination
of CBD enhanced Ayurvedic herbs
in vaping cartridges and in topicals. Other cannabinoids may be
added to the hempOLOGY product line.
About Freedom Leaf
Freedom Leaf, Inc., The Marijuana Legalization Company™, is a
fully reporting and audited, publicly traded company trading under
the symbol (OTCQB: FRLF). Freedom Leaf, Inc. is a leading
go-to resource in the cannabis, medical marijuana, and industrial
hemp industry. It is involved in mergers and acquisitions in the
marijuana industry, including incubation/acceleration and spin offs
of new marijuana/hemp related companies.
Freedom Leaf Inc.'s flagship publication is Freedom
Leaf Magazine, The Good News in Marijuana Reform. The
company produces a portfolio of news, print and digital multi-media
verticals, websites, and web advertising, for the ever-changing
emerging cannabis, medical marijuana and industrial hemp
industry.
Freedom Leaf, Inc. does not handle, grow, sell, or disperse
marijuana.
Investor relations information can be found on
the FreedomLeafInc.com company website.
Safe Harbor Statement
Statements in this press release that are not strictly
historical are "forward-looking" statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements generally can be identified by phrases
such as Freedom Leaf, Inc. or its management "believes," "expects,"
"anticipates," "foresees," "forecasts," "estimates" or other words
or phrases of similar import. Similarly, statements herein that
describe the Company's business strategy, outlook, objectives,
plans, intentions or goals also are forward-looking statements. All
such forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those in forward-looking statements. Factors that could cause
or contribute to differences include the uncertainty regarding
viability and market acceptance of the Company's products and
services, changes in relationships with third parties, and other
factors described in the Company's most recent periodic filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K dated June 30, 2016 and quarterly reports on
Form 10-Q.